Topical retinoids are vitamin A derivatives with more randomised controlled trial data behind them than almost any other class of skincare active. Tretinoin, the most potent topical retinoid, is prescription-only in the UK. Adapalene 0.1% is available without prescription. Retinol sits in the cosmetic market. Each occupies a different regulatory lane, and understanding that distinction shapes how UK aesthetic practitioners advise, recommend, and refer.
What Topical Retinoids Are and How They Work
Retinoids bind to nuclear retinoic acid receptors (RARs), which regulate gene expression in keratinocytes and fibroblasts. The clinical effects (reduced comedone formation, increased collagen turnover, melanin redistribution) all follow from that receptor binding.
The hierarchy from most to least potent:
- Tretinoin (all-trans retinoic acid): the active acid form that binds directly to RARs. Prescription-only in the UK (POM).
- Adapalene: a third-generation synthetic retinoid with more selective RAR binding and a better tolerability profile than tretinoin. Available OTC at 0.1% following MHRA reclassification; 0.3% strength remains POM.
- Retinaldehyde: one enzymatic conversion step from tretinoin. A cosmetic ingredient.
- Retinol: two steps from tretinoin. The standard OTC retinoid in the UK skincare market.
- Retinyl esters (retinyl palmitate, retinyl acetate): three steps from tretinoin. Lowest potency. Common in mainstream formulations.
Each conversion step represents a drop in efficacy. That is the trade-off between potency and tolerability, the practical question practitioners navigate when selecting between prescription and OTC retinoid options.
The Evidence for Acne Treatment
NICE guideline NG198 places topical retinoids at the centre of acne management. The guideline recommends a topical retinoid, alone or in combination with a topical antibiotic, for mild-to-moderate acne, and recognises their role in maintenance after inflammation is controlled.
The mechanism is well characterised. Retinoids inhibit microcomedone formation, the precursor lesion common to both inflammatory and non-inflammatory acne, by normalising follicular keratinocyte differentiation and reducing follicular plugging. Tretinoin has the longest published evidence base. Adapalene has comparable comedolytic activity with a better tolerability record, which makes it the practical first choice for patients with sensitive skin.
A 2025 review of topical tretinoin across dermatological conditions confirmed robust RCT-level support for its use in acne, with consistent reduction in both inflammatory and non-inflammatory lesion counts. The review also noted tretinoin's value alongside antibiotic combinations: the retinoid component addresses the comedonal element that antibiotics do not, reducing the selective pressure that drives antimicrobial resistance over time.
For non-prescribing UK practitioners, scope is the key variable. Recommending OTC adapalene 0.1% sits within reach for any practitioner with the competence to do so safely. Tretinoin requires either a prescribing practitioner in the team or a referral pathway to one.
The Evidence for Photoaging
The photoaging evidence base for topical retinoids is as strong as anything in aesthetic medicine. A focused review of retinoids in antiaging treatments identified consistent histological and clinical improvements with tretinoin across multiple RCTs: increased dermal collagen deposition, improved epidermal thickness, reduction of fine lines, and correction of mottled hyperpigmentation.
The mechanisms behind these effects are distinct from the acne pathway:
Collagen induction. Tretinoin stimulates fibroblast proliferation and upregulates type I and III procollagen synthesis. It simultaneously inhibits matrix metalloproteinases (MMPs), which degrade existing collagen. The net result, over months of consistent use, is measurable increase in dermal collagen density.
Melanin redistribution. Tretinoin accelerates epidermal turnover, dispersing concentrated melanin deposits and normalising keratinocyte differentiation. This is why it features in combination protocols for photoaged, mottled skin and for hyperpigmentation where postinflammatory pigment is a component.
Epidermal remodelling. Tretinoin thickens the epidermis after an initial thinning phase, improving barrier integrity and surface texture.
Clinical improvement with tretinoin for photoaging requires sustained use, typically 12 to 24 weeks before visible change, with continued improvement over a year of consistent application. Setting that expectation accurately is part of clinical competence in managing these treatments.
The Prescribing Boundary in UK Practice
The MHRA classifies tretinoin as a POM. Any practitioner issuing a tretinoin prescription must be a registered prescriber: a doctor, nurse independent prescriber, pharmacist prescriber, or another suitably qualified prescribing clinician.
What this means in practice:
- Prescribing practitioners can issue tretinoin as part of a treatment plan for acne or photoaging.
- Non-prescribing practitioners can recommend and supply OTC adapalene 0.1% and retinol-based cosmetics, within their clinical competence. They cannot supply tretinoin. A referral pathway to a prescribing colleague is good practice for any clinic managing acne or significant photoaging.
- All practitioners should know that patients self-importing tretinoin via online pharmacies is common. The clinical conversation about tolerability, photosensitivity, and contraindications applies regardless of who issued the prescription.
The distinction between cosmetic retinol and medicinal tretinoin matters, because clients frequently use the terms interchangeably. Clarity from the practitioner prevents both underestimating OTC retinol and inadvertently appearing to prescribe when not qualified to do so.
This is precisely the kind of scope question that sits at the heart of regulation in UK aesthetics: knowing not just what a treatment does, but what you are authorised to do within your registration and training.
Tolerability and Patient Selection
Retinoid dermatitis, including erythema, dryness, peeling, and photosensitivity, is the most common reason patients discontinue. Evidence supports a gradual introduction: begin at the lowest available strength, once or twice weekly, building to nightly over six to eight weeks. Moisturiser use and broad-spectrum sun protection are essential throughout.
Key selection considerations:
- Dry or sensitive skin: start with retinol or adapalene 0.1% rather than tretinoin.
- Rosacea or eczema history: adapalene has the better tolerability record in reactive skin.
- Pregnancy and breastfeeding: topical retinoids are contraindicated. Although transdermal absorption from topical tretinoin is low, the teratogenic risk of the retinoid class means the contraindication stands in UK clinical guidance.
- Darker skin tones: retinoid-induced irritation can trigger postinflammatory hyperpigmentation. A gradual introduction and concurrent barrier support reduce this risk significantly.
- Periorbital area: full-strength tretinoin is poorly tolerated around the eyes; purpose-formulated, lower-concentration retinol is used here.
Autumn and retinoid reintroduction in clinical practice
September and October are the natural reintroduction window for retinoids in UK practice. Summer UV intensity and patient behaviour, including more time outdoors without consistent sun protection, lead many practitioners to pause or reduce retinoid use through June to August. As UV index falls and the summer travel season ends, the practical conditions for consistent retinoid use improve. Starting in September gives a 6 to 8 month lower-UV period: enough to establish the retinoid, see clinical improvement, and reassess before the following spring.
Several considerations shape that autumn restart.
Reintroduction after a gap. A patient who paused retinoids for 8 to 12 weeks should restart at the same gradual pace used for a first introduction, not pick up where they left off. The skin loses acclimatisation during a break. A return to nightly tretinoin after a summer gap carries the same retinoid-dermatitis risk as a first prescription.
Post-summer barrier assessment. Summer sun exposure commonly leaves the epidermal barrier compromised, even without visible burn. Before reintroducing a retinoid, a brief barrier-repair phase, if indicated, reduces the risk of retinoid irritation compounding existing barrier disruption. The same moisturiser-first, gradual-frequency approach that governs first-time use applies here.
Melanin dynamics and autumn pigment protocols. Post-summer pigmentation and the autumn retinoid season coincide usefully. Tretinoin accelerates epidermal turnover and disperses concentrated melanin, making autumn the established season for pigment-focused combination protocols. Starting in September gives adequate runway before the following summer for retinoids to work alongside other actives, including azelaic acid and niacinamide. For practitioners developing post-summer pigment plans, the free Hyperpigmentation Decoded Mini is a three-lesson clinical introduction to pigment assessment and treatment sequencing at no cost. The full Hyperpigmentation Decoded programme covers the evidence base in depth.
Patient timeline framing. Setting the retinoid programme within an autumn-to-spring frame gives patients a concrete narrative. 12 to 24 weeks to measurable change, across the low-UV months, is a timeline most patients can engage with. It also positions the end-of-year review as a natural checkpoint.
For the rosacea-prone patient, autumn is also when seasonal flushing drivers change. Any retinoid decision for rosacea skin should account for the shift in triggers, not just the UV calendar.
Putting It Into Clinical Practice
Retinoids are not a shortcut or an add-on. They are a sustained therapeutic commitment, and the practitioners who get the best outcomes are those who manage the initiation phase well, set realistic timelines, and integrate retinoids into a broader treatment plan rather than treating them as a standalone fix. That structured approach to skin health, combining ingredient science with clinical judgement and regulatory literacy, is what the Acne Decoded programme is built on, including where retinoids sit alongside other actives and when referral is the right call.
FAQ
Are topical retinoids prescription-only in the UK? Not all of them. Tretinoin and adapalene 0.3% are prescription-only medicines (POM) in the UK. Adapalene 0.1% (Differin) is available without prescription following MHRA reclassification. Retinol and retinyl esters are cosmetic ingredients, with no prescription required.
Can a non-prescribing aesthetic practitioner recommend retinoids? Yes, within limits. Non-prescribing practitioners can recommend OTC adapalene 0.1% and retinol-based products where they have the knowledge to do so safely. They cannot prescribe or supply tretinoin or adapalene 0.3%. A referral pathway to a prescribing colleague is good clinical governance for any practice treating acne or photoaging.
How long does tretinoin take to show results for photoaging? Most published evidence shows clinical improvement at 12 to 24 weeks, with continued change over 12 months of consistent use. The first four to six weeks often involve a retinoid reaction phase before the skin stabilises. Realistic expectation-setting is as important as the prescription itself.
Is retinol as effective as tretinoin? Retinol must be converted by the skin before becoming active, which reduces its potency relative to tretinoin. For mild indications or in patients who cannot tolerate tretinoin, retinol offers measurable but attenuated benefit. For moderate-to-severe acne or significant photoaging, tretinoin has a substantially stronger evidence base.
Can retinoids be used with other actives? Some combinations are well-supported: retinoids with niacinamide (which reduces retinoid-associated erythema) and retinoids with azelaic acid for hyperpigmentation are both used in clinical practice. Combinations with exfoliating acids or benzoyl peroxide require careful timing or alternation to avoid cumulative irritation. This is ingredient-specific decision-making, not a blanket compatibility rule.
When is the best time of year to start or restart a retinoid? Autumn, from September onwards, is the practical window most UK practitioners use. Falling UV index reduces the photosensitivity risk that makes consistent summer use difficult, and the 6 to 8 lower-UV months that follow are long enough to establish the retinoid and see measurable improvement before the following spring. Patients restarting after a summer pause should return to a gradual introduction rather than picking up at their last dose.